
Valneva reports positive Phase 2 results for its tetravalent Shigella vaccine candidate showing safety and efficacy.
Valneva announced positive Phase 2 trial results for its tetravalent Shigella vaccine candidate S4V2, showing a favorable safety profile and encouraging immune responses in infants and adults. The infant trial in Kenya demonstrated significant antibo...





